<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802512</url>
  </required_header>
  <id_info>
    <org_study_id>HatayMustafaKU</org_study_id>
    <nct_id>NCT04802512</nct_id>
  </id_info>
  <brief_title>Turkish Version of Telehealth Usability Questionnaire (TUQ)</brief_title>
  <official_title>Investigation of the Turkish Validity and Reliability of the Telehealth Usability Questionnaire (TUQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irem Hüzmeli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mustafa Kemal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Telehealth Usability Questionnaire (TUQ) was developed to evaluate the usability of&#xD;
      telehealth applications and services. The Turkish validity and reliability study of the&#xD;
      scale, originally in English, has not been conducted before.&#xD;
&#xD;
      The aim of this study is to develop the Turkish version of the Telehealth Usability&#xD;
      Questionnaire (TUQ), which is a new stability tool, and to report its reliability assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Telehealth Usability Questionnaire (TUQ) turkish version will be asked by using google&#xD;
      forms to participants whom use telehealth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">June 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>15 Days</target_duration>
  <primary_outcome>
    <measure>Reliability and Validity of TUQ by Correlation Analysis.</measure>
    <time_frame>12 month</time_frame>
    <description>with telehealth will be researched</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Health Care Acceptor</condition>
  <condition>Health Knowledge, Attitudes, Practice</condition>
  <condition>Patient Participation</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>patients who were used telehealth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>health professional</arm_group_label>
    <description>health professional who were used telehealth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>validity and reability study</intervention_name>
    <description>validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)</description>
    <arm_group_label>health professional</arm_group_label>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Turkish validity and reliability of the scale, which was created to evaluate the&#xD;
        usability of the telehealth service for service users (patients) and providers (health&#xD;
        professional), will be investigated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants will undergo screening to confirm eligibility, completion of initial screening&#xD;
        form, and MMSE evaluation. Study subjects were enrolled with MMSE scores between 29-30,&#xD;
        inclusive (healthy/control), 25-28, inclusive (mild cognitive impairment), and 10-24&#xD;
        (dementia).&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to complete computerized and standard pencil-and-paper based assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irem Huzmeli, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Mustafa Kemal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esra Dogru Huzmeli, Assoc Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mustafa Kemal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet Karadağ, Asist. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Mustafa Kemal University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irem huzmeli, Phd</last_name>
    <phone>+90326221 33 17</phone>
    <email>fztirem@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esra Dogru huzmeli, Assoc. prof.</last_name>
    <phone>+90326221 33 17</phone>
    <email>edogru001@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hatay Mustafa Kemal University</name>
      <address>
        <city>Hatay</city>
        <state>Merkez</state>
        <zip>31010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irem Hüzmeli, PHD</last_name>
      <phone>+90 (326) 221 33 17</phone>
      <phone_ext>15550</phone_ext>
      <email>fztirem@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Irem Hüzmeli, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esra Dogru Huzmeli, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehmet Karadag, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Online</name>
      <address>
        <city>Hatay</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>irem huzmeli, phd</last_name>
      <phone>+903262213317</phone>
      <email>fztirem@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mustafa Kemal University</investigator_affiliation>
    <investigator_full_name>Irem Hüzmeli</investigator_full_name>
    <investigator_title>Phd lecturer</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

